Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Baxter
Colorcon
Moodys
Medtronic

Last Updated: January 30, 2023

Trilaciclib dihydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for trilaciclib dihydrochloride and what is the scope of freedom to operate?

Trilaciclib dihydrochloride is the generic ingredient in one branded drug marketed by G1 Therap and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trilaciclib dihydrochloride has one hundred and ten patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for trilaciclib dihydrochloride
International Patents:110
US Patents:10
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 13
DailyMed Link:trilaciclib dihydrochloride at DailyMed
Recent Clinical Trials for trilaciclib dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
UNC Lineberger Comprehensive Cancer CenterPhase 2
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 4
G1 Therapeutics, Inc.Phase 4

See all trilaciclib dihydrochloride clinical trials

US Patents and Regulatory Information for trilaciclib dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for trilaciclib dihydrochloride

Country Patent Number Title Estimated Expiration
Japan 2013543845 See Plans and Pricing
Denmark 2968290 See Plans and Pricing
China 103429243 CDK inhibitors See Plans and Pricing
China 104045654 CDK inhibitors See Plans and Pricing
South Korea 20190135556 CDK 억제제 (CDK CDK INHIBITORS) See Plans and Pricing
European Patent Office 3653209 PROTECTION TRANSITOIRE DE CELLULES NORMALES PENDANT LA CHIMIOTHÉRAPIE (TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Medtronic
Boehringer Ingelheim
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.